Lopinavir/Ritonavir Accord

Lopinavir, the active ingredient in Lopinavir/Ritonavir Accord, is a protease inhibitor presented as a fixed‑dose oral tablet for oral use. It is combined with ritonavir to treat Human Immunodeficiency Virus (HIV) infection in adults and adolescents, and the ritonavir component boosts lopinavir plasma concentrations to enhance antiviral efficacy.

GNH USA supplies Lopinavir/Ritonavir Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable access to quality‑assured medication across multiple regions.

Lopinavir/ritonavir is used as part of antiretroviral therapy for HIV infection, targeting viral replication. - HIV‑1 infection (adults): reduces viral load and improves immune function. - HIV‑1 infection (adolescents): part of combination regimens to achieve viral suppression. - HIV‑1 infection (children): used in pediatric formulations to control disease progression.

Lopinavir/ritonavir may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools. - Nausea: feeling of sickness. - Headache: mild to moderate pain. - Elevated triglycerides: increase in blood lipid levels.

Serious or Rare Side Effects: - Hepatotoxicity: liver enzyme elevations or hepatitis. - Pancreatitis: inflammation of the pancreas. - Severe allergic reactions: rash, angioedema, or anaphylaxis.

When prescribing Lopinavir/ritonavir, clinicians should consider several precautionary measures to ensure safe use. - Baseline liver function: assess hepatic enzymes before initiating therapy. - Lipid monitoring: check triglyceride and cholesterol levels regularly. - Drug resistance: avoid use in patients with known protease inhibitor resistance. - Pregnancy considerations: evaluate risks versus benefits in pregnant patients. - Concomitant medications: review for potential interactions, especially with CYP3A4 substrates. - Store at ambient temperature: keep tablets in original container, protect from moisture and heat.

Lopinavir/ritonavir interacts with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce lopinavir levels. - Certain antiarrhythmics (e.g., amiodarone): may cause cardiac toxicity. - HIV integrase inhibitors (e.g., dolutegravir) without dose adjustment: risk of reduced efficacy.

Moderate Interactions (Monitor Closely): - Statins (e.g., simvastatin, lovastatin): increased risk of myopathy. - Sedatives (e.g., midazolam): enhanced central nervous system depression. - Oral contraceptives: possible reduction in contraceptive effectiveness.